Cancer in Georgia

IARC estimates 16,063 new cancer cases and 7,780 cancer deaths in Georgia in 2024; the commonest new cancers are breast, trachea, bronchus and lung and prostate. This page is assembled automatically from OnCo's data: 77 trials with a site there, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

16,063

all cancers

Deaths

7,780

all cancers

Incidence rate

234.4

per 100,000, age-standardised

Mortality rate

109.2

per 100,000, age-standardised

Cumulative risk

22.7%

of a cancer by age 74

Population

3,807,673

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Breast	2,064	53.8	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Trachea, bronchus and lung	1,402	21.1	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Prostate	1,335	44.4	Prostate cancer
Colorectum	1,293	17.7	Colorectal cancer
Corpus uteri	717	17.4	Endometrial cancer
Bladder	700	8.7	Bladder & urothelial cancer
Stomach	683	9.3	Gastric & gastro-oesophageal junction cancer
Thyroid	628	11.2	Thyroid cancer
Cervix uteri	591	17.0	Cervical cancer
Liver and intrahepatic bile ducts	588	9.1	Hepatocellular carcinoma

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	1,213	17.8	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	604	8.0	Colorectal cancer
Breast	602	14.9	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Stomach	520	6.9	Gastric & gastro-oesophageal junction cancer
Liver and intrahepatic bile ducts	512	7.7	Hepatocellular carcinoma
Pancreas	382	5.0	Pancreatic ductal adenocarcinoma
Prostate	357	11.8	Prostate cancer
Leukaemia	282	4.1	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Brain, central nervous system	278	4.7	Glioma & glioblastoma
Bladder	275	3.3	Bladder & urothelial cancer

Incidence: method 3c, national mortality estimates applied to model-based mortality-to-incidence ratios (registry survival data).
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Georgia”, in Western Asia (Asia), Very High HDI, upper middle income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

77 trials in OnCo · 28 recruiting overall

77 trials

Trial			Lead sponsor
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) NCT06345729	Phase 3	Recruiting	Merck Sharp & Dohme LLC	241	2026-10-07
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer NCT07173751	Phase 3	Recruiting	BioNTech SE	212	2026-10-06
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies NCT05006716	Phase 1/2	Recruiting	BeOne Medicines	114	2026-10-05
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma NCT07562152	Phase 3	Recruiting	Immuneering Corporation	57	2026-10-05
A Platform Study in Non-Small Cell Lung Cancer (NSCLC) NCT06996782	Phase 1/2	Recruiting	AstraZeneca	103	2026-10-01
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 NCT06219941	Phase 2	Recruiting	AstraZeneca	52	2026-09-30
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment NCT07472517	Phase 3	Recruiting	Boehringer Ingelheim	245	2026-09-29
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer NCT06868277	Phase 3	Recruiting	AstraZeneca	304	2026-09-25
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC NCT04892173	Phase 3	Recruiting	Johnson & Johnson Enterprise Innovation Inc.	193	2026-09-25
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation NCT07211958	Phase 3	Recruiting	Syndax Pharmaceuticals	149	2026-09-25
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma NCT07069712	Phase 2	Recruiting	AstraZeneca	70	2026-09-24
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma NCT07522073	Phase 3	Recruiting	Incyte Corporation	228	2026-09-22
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer NCT06712316	Phase 2/3	Recruiting	BioNTech SE	365	2026-09-22
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer NCT06827236	Phase 1/2	Recruiting	BioNTech SE	79	2026-09-17
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) NCT07625644	Phase 3	Recruiting	SystImmune Inc.	62	2026-09-17
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G NCT04613596	Phase 2/3	Recruiting	Mirati Therapeutics Inc.	770	2026-09-16
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence NCT06492616	Phase 3	Recruiting	Stemline Therapeutics, Inc.	567	2026-09-15
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer NCT07284849	Phase 3	Recruiting	Incyte Corporation	280	2026-09-15
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer NCT06774131	Phase 3	Recruiting	UroGen Pharma Ltd.	79	2026-09-03
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy NCT05774951	Phase 3	Recruiting	AstraZeneca	709	2026-08-19
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Re NCT06788756	Phase 2/3	Recruiting	Moleculin Biotech, Inc.	28	2026-08-05
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) NCT07044336	Phase 3	Recruiting	AstraZeneca	320	2026-07-29
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers NCT05098132	Phase 1/2	Recruiting	Synthekine	47	2026-07-21
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors NCT04219254	Phase 1/2	Recruiting	BioInvent International AB	26	2026-06-25
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC NCT05491525	Phase 2/3	Recruiting	Urovant Sciences GmbH	38	2026-06-15
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. NCT07033026	Phase 2	Recruiting	NGM Biopharmaceuticals, Inc	28	2026-04-01
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer NCT06532006	Phase 3	Recruiting	Shanghai Henlius Biotech	208	2026-02-27
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer NCT05797831	Phase 2/3	Recruiting	Kartos Therapeutics, Inc.	83	2024-05-02
XPORT-EC-042 / ENGOT-EN20 / GOG-3083 NCT05611931	Phase 3	Active not recruiting	Karyopharm Therapeutics Inc	191	2026-09-30
Volrustomig Priming Regimens Exploratory Phase II Platform Study NCT06448754	Phase 2	Active not recruiting	AstraZeneca	63	2026-09-29

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Georgia, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Georgia is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

OnCo holds no institution, company or person in Georgia.

Approvals

OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Georgia is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Georgia's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Georgia, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines regulator, its approval routes and its decisions.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Georgia's own sources.

Georgia is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/ge.json; every country: /api/v1/countries.json.